Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:00603375 | Esophagus | ESCC | type I interferon signaling pathway | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:00713575 | Esophagus | ESCC | cellular response to type I interferon | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
GO:00354555 | Esophagus | ESCC | response to interferon-alpha | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
GO:00343404 | Liver | Cirrhotic | response to type I interferon | 29/4634 | 58/18723 | 2.87e-05 | 3.64e-04 | 29 |
GO:00713572 | Liver | Cirrhotic | cellular response to type I interferon | 24/4634 | 52/18723 | 6.32e-04 | 4.83e-03 | 24 |
GO:00603372 | Liver | Cirrhotic | type I interferon signaling pathway | 23/4634 | 50/18723 | 8.62e-04 | 6.22e-03 | 23 |
GO:0035456 | Liver | Cirrhotic | response to interferon-beta | 15/4634 | 32/18723 | 5.36e-03 | 2.73e-02 | 15 |
GO:0035455 | Liver | Cirrhotic | response to interferon-alpha | 11/4634 | 21/18723 | 5.89e-03 | 2.95e-02 | 11 |
GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:003434011 | Liver | HCC | response to type I interferon | 43/7958 | 58/18723 | 9.93e-07 | 1.50e-05 | 43 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:006033711 | Liver | HCC | type I interferon signaling pathway | 37/7958 | 50/18723 | 6.13e-06 | 7.52e-05 | 37 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa05171310 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa05165 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFNAR2 | SNV | Missense_Mutation | rs866733383 | c.1349N>T | p.Ser450Leu | p.S450L | P48551 | protein_coding | tolerated(0.28) | benign(0.08) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | | c.1271A>T | p.Asn424Ile | p.N424I | P48551 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
IFNAR2 | SNV | Missense_Mutation | | c.1324N>A | p.Asp442Asn | p.D442N | P48551 | protein_coding | tolerated(0.19) | benign(0.07) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
IFNAR2 | SNV | Missense_Mutation | | c.577N>G | p.Phe193Val | p.F193V | P48551 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
IFNAR2 | SNV | Missense_Mutation | rs545884061 | c.503N>G | p.Leu168Arg | p.L168R | P48551 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
IFNAR2 | SNV | Missense_Mutation | novel | c.1037N>T | p.Pro346Leu | p.P346L | P48551 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | novel | c.346N>G | p.Asn116Asp | p.N116D | P48551 | protein_coding | tolerated(0.23) | benign(0.039) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | novel | c.520N>C | p.Ser174Pro | p.S174P | P48551 | protein_coding | deleterious(0.04) | possibly_damaging(0.872) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | rs375487848 | c.145N>T | p.Arg49Trp | p.R49W | P48551 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-D1-A2G0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | rs866733383 | c.1349C>T | p.Ser450Leu | p.S450L | P48551 | protein_coding | tolerated(0.28) | benign(0.08) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201560 | PEGINTERFERON ALFA-2A | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | | INTERFERON BETA-1B | | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | | INTERFERON ALFACON-1 | | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | | Interferon Alfa-2b, Recombinant | | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201558 | INTERFERON ALFA-2B | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | | Interferon alfa-n1 | | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201557 | INTERFERON ALFACON-1 | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL2108677 | PEGINTERFERON BETA-1A | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201563 | INTERFERON BETA-1B | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | | Anifrolumab | ANIFROLUMAB | |